Amgen to delay earnings report for study results
- Share via
From Reuters
Amgen Inc. said it would delay reporting first-quarter earnings until April 23 to include data from an anxiously anticipated study of its Aranesp anemia drug among patients with small-cell lung cancer.
The Thousand Oaks-based biotech company said it would include “top-line results,” meaning important but limited data, from the “145 study,” which involved patients who had the less common form of lung cancer and were undergoing chemotherapy.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
